SRZN Logo

Surrozen, Inc. (SRZN) Stock Forecast & Price Prediction

Live SRZN Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$10.00

-0.41 (-3.94%)

12 Month Price Forecast For SRZN

$10.00
Current Price
$32.50M
Market Cap
2 Ratings
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to SRZN Price Forecasts

+350.0%
To High Target of $45.00
+285.0%
To Median Target of $38.50
+220.0%
To Low Target of $32.00

SRZN Price Momentum

-11.6%
1 Week Change
-10.3%
1 Month Change
+14.3%
1 Year Change
-30.3%
Year-to-Date Change
-45.0%
From 52W High of $18.17
+66.7%
From 52W Low of $6.00

๐Ÿค” Considering Surrozen (SRZN)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 2:58 PM UTC

SRZN Analyst Ratings & Price Targets

Based on our analysis of 5 Wall Street analysts, SRZN has a bullish consensus with a median price target of $38.50 (ranging from $32.00 to $45.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $10.00, the median forecast implies a 285.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Yatin Suneja at Guggenheim, projecting a 350.0% upside. Conversely, the most conservative target is provided by Matthew Caufield at HC Wainwright & Co., suggesting a 220.0% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

SRZN Analyst Consensus

2
Buy
0
Hold
0
Sell

SRZN Price Target Range

Low
$32.00
Average
$38.50
High
$45.00
Current: $10.00

Latest SRZN Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for SRZN.

Date Firm Analyst Rating Change Price Target
Jan 30, 2025 HC Wainwright & Co. Matthew Caufield Buy Initiates $32.00
Jan 3, 2025 Guggenheim Yatin Suneja Buy Upgrade $45.00
Nov 29, 2022 JP Morgan Eric Joseph Underweight Downgrade $0.00
Nov 18, 2022 Guggenheim Yatin Suneja Neutral Downgrade $0.00
Nov 17, 2022 B of A Securities Tazeen Ahmad Underperform Downgrade $1.00
Oct 17, 2022 JP Morgan Eric Joseph Neutral Initiates $0.00
May 27, 2022 B of A Securities Tazeen Ahmad Neutral Downgrade $5.00
Oct 11, 2021 B of A Securities Buy Initiates $0.00
Sep 15, 2021 Guggenheim Buy Initiates $0.00
Sep 7, 2021 Stifel Buy Initiates $0.00

Stocks Similar to Surrozen, Inc.

The following stocks are similar to Surrozen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Surrozen, Inc. (SRZN) Financial Data

Surrozen, Inc. has a market capitalization of $32.50M with a P/E ratio of -0.5x. The company generates $10.00M in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of +12.3% and return on equity of -173.6%.

Valuation Metrics

Market Cap $32.50M
Enterprise Value $4.12M
P/E Ratio -0.5x
PEG Ratio -2.2x
Price/Sales 3.2x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin +12.3%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +96.1%
Current Ratio 7.4x
Debt/Equity 26.9x
ROE -173.6%
ROA -32.6%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Surrozen, Inc. logo

Surrozen, Inc. (SRZN) Company Overview

About Surrozen, Inc.

What They Do

Biotechnology company developing Wnt pathway therapeutics.

Business Model

Surrozen, Inc. operates as a clinical stage biotechnology firm focused on discovering and developing drug candidates that modulate the Wnt pathway for tissue repair. The company generates revenue through collaborations and licensing agreements, such as its partnership with Boehringer Ingelheim, while advancing its own pipeline of antibody-based therapeutics targeting various diseases.

Additional Information

The company is currently advancing several products in clinical trials, including SZN-043 for severe liver diseases and SZN-413 for retinal vascular diseases. With a strong focus on the Wnt pathway, Surrozen aims to address unmet medical needs across multiple organ systems, positioning itself for potential future growth in the biotechnology sector.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

42

CEO

Mr. Craig C. Parker M.B.A.

Country

United States

IPO Year

2021

Surrozen, Inc. (SRZN) Latest News & Analysis

SRZN stock latest news image
Quick Summary

Surrozen, Inc. reports progress in its Phase 1b trial for SZN-043 in severe alcohol-associated hepatitis, with data expected in H1 2025. The company also received a $10 million milestone payment from Boehringer Ingelheim.

Why It Matters

Surrozen's progress in clinical trials and new preclinical candidates enhances growth potential, while the $10 million milestone boosts financial stability, signaling positive momentum for investors.

Source: GlobeNewsWire
Market Sentiment: Neutral
SRZN stock latest news image
Quick Summary

Surrozen, Inc. has entered a research collaboration with TCGFB, Inc. to develop antibody therapeutics targeting TGF-ฮฒ for idiopathic pulmonary fibrosis (IPF) treatment.

Why It Matters

The collaboration between Surrozen and TCGFB could enhance Surrozen's pipeline and market position in fibrosis treatments, potentially boosting investor confidence and company valuation.

Source: GlobeNewsWire
Market Sentiment: Neutral
SRZN stock latest news image
Quick Summary

Surrozen, Inc. (Nasdaq: SRZN) announced that CEO Craig Parker will present at two healthcare investor conferences, focusing on their targeted therapeutics for tissue repair.

Why It Matters

Surrozen's CEO presenting at healthcare conferences signals potential investor interest and visibility, which may impact stock performance and market perception of the company's growth prospects.

Source: GlobeNewsWire
Market Sentiment: Neutral
SRZN stock latest news image
Quick Summary

Boehringer Ingelheim is advancing SZN-413, a bi-specific antibody targeting Fzd4 for retinal vascular diseases, towards future clinical testing, as announced by Surrozen, Inc. on Sept. 24, 2024.

Why It Matters

Boehringer's advancement of SZN-413 for retinal diseases signals potential breakthroughs in treatment, impacting Surrozen's stock value and future revenue prospects.

Source: GlobeNewsWire
Market Sentiment: Neutral
SRZN stock latest news image
Quick Summary

Surrozen, Inc. is conducting a Phase 1b trial for SZN-043 targeting Severe Alcoholic Hepatitis and reported Phase 1a data. The company also shared Q2 2024 financial results and updates.

Why It Matters

Surrozen's advancement in clinical trials for Severe Alcoholic Hepatitis and innovative technologies could enhance its market position, potentially impacting stock performance and investor sentiment.

Source: GlobeNewsWire
Market Sentiment: Neutral
SRZN stock latest news image
Quick Summary

Surrozen's SZN-043, a novel biotherapeutic, showed safety and efficacy in Phase 1a trials for liver cirrhosis. Enrollment continues in a Phase 1b study for severe alcohol-associated hepatitis.

Why It Matters

SZN-043 shows promise in treating liver conditions, with safe Phase 1a results. Positive outcomes may boost Surrozen's stock and market position in biotherapeutics for liver diseases.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About SRZN Stock

What is Surrozen, Inc.'s (SRZN) stock forecast for 2025?

Based on our analysis of 5 Wall Street analysts, Surrozen, Inc. (SRZN) has a median price target of $38.50. The highest price target is $45.00 and the lowest is $32.00.

Is SRZN stock a good investment in 2025?

According to current analyst ratings, SRZN has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.00. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for SRZN stock?

Wall Street analysts predict SRZN stock could reach $38.50 in the next 12 months. This represents a 285.0% increase from the current price of $10.00. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Surrozen, Inc.'s business model?

Surrozen, Inc. operates as a clinical stage biotechnology firm focused on discovering and developing drug candidates that modulate the Wnt pathway for tissue repair. The company generates revenue through collaborations and licensing agreements, such as its partnership with Boehringer Ingelheim, while advancing its own pipeline of antibody-based therapeutics targeting various diseases.

What is the highest forecasted price for SRZN Surrozen, Inc.?

The highest price target for SRZN is $45.00 from Yatin Suneja at Guggenheim, which represents a 350.0% increase from the current price of $10.00.

What is the lowest forecasted price for SRZN Surrozen, Inc.?

The lowest price target for SRZN is $32.00 from Matthew Caufield at HC Wainwright & Co., which represents a 220.0% increase from the current price of $10.00.

What is the overall SRZN consensus from analysts for Surrozen, Inc.?

The overall analyst consensus for SRZN is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $38.50.

How accurate are SRZN stock price projections?

Stock price projections, including those for Surrozen, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.